Lifecore Biomedical (LFCR)
Develops and manufactures sterile injectable products and pharmaceutical-grade hyaluronic acid.
Something off on this page? Send us feedback.
Provides development, formulation, cGMP manufacturing, and aseptic fill-finish for sterile injectable pharmaceutical and medical-device products. Its fermentation-based hyaluronic-acid capability supplies pharmaceutical-grade HA as bulk material and in formulated, filled injectable products.
Develops, formulates, and manufactures sterile injectable pharmaceutical and medical-device products, including filled syringes, vials, and cartridges. Its integrated CDMO services cover development, cGMP manufacturing, formulation, and aseptic fill-finish, alongside pharmaceutical-grade hyaluronic acid supplied as bulk material and used in formulated products.
Operations are concentrated in Chaska, Minnesota, and its full-time workforce was entirely based in the United States as of the context filing. The business depends on fermentation-based HA capability and on executing sterile manufacturing and aseptic filling for complex products. It has operated as a standalone integrated CDMO since divesting its former food businesses.
Company facts
Target rangeAs of Sep 21, 2026
Latest analyst notes
| Date | Firm | Action | Prior | Current |
|---|---|---|---|---|
| Jun 16, 2026 | Barrington | Target | Target: $6 | Target: $6.50 |
| Apr 29, 2026 | Barrington | Target | Target: — | Target: $6 |
| Mar 17, 2026 | Barrington Research | Upgrade |
EPSReportedEstimate
RevenueReportedEstimate
Balance sheet, Jun 30, 2026Cash & short-term investments $17.2M · Total debt $155.1M · Total assets $229.5M · Shareholders' equity −$34.1M
- Revenue
- $34.2M
- Operating income
- $2.6M
- Net income
- −$6.2M
No dividends on record.
| Institutions | 67.37% | 25.50M shares | |
|---|---|---|---|
| 104 holders · as of Jun 30, 2026 | |||
| Insiders | 23.99% | 9.08M shares | |
| 13 holders · as of Jun 8, 2026 | |||
| Strategic holders | 12.42% | 4.70M shares | |
| 1 holder · as of Oct 7, 2024 | |||
| Adds to | 103.78% | ||
37.85M company shares as of Sep 22, 2026 · institutions as of Jun 30, 2026 · holders as of their latest filing
These groups come from separate filings that can overlap, so they add to 103.78%; nothing is left for Other.
Top shareholders13F · 13D/G · Form 4
| Holder | Stake | Shares | Date |
|---|---|---|---|
Nelson Obus1Insiderdirector | 13.43% | 5.01M | filed Jun 5, 2026 |
Wynnefield Capital IncInstitution | 12.42% | 4.70M | as of Jun 30, 2026 |
Wynnefield Partners Small Cap Value LP IStrategic10 percent owner | 12.42% | 4.70M | filed Oct 7, 2024 |
Legion Partners Asset Management, LLCInstitution | 11.79% | 4.46M | as of Jun 30, 2026 |
Greenhaven Road Investment Management, L.P.Institution | 8.43% | 3.19M | as of Jun 30, 2026 |
- Nelson Obus's transaction reports restate only vehicles that traded; the 2024 ownership statement (5.01M) plus the 75.4K net shares acquired since is used instead.
Insider tradesForm 4
No open-market trades in the last 12 months.
- Thermo Fisher Scientific
End-to-end CDMO with sterile injectable fill-finish capabilities
Compare
| Company | Price | Change | |||||
|---|---|---|---|---|---|---|---|
| Lifecore Biomedical | $4.48 | 0.00% | $168.0M | — | — | — | −6.3% |
| Thermo Fisher Scientific | $657.60 | −0.18% | $244.81B | 35.4 | 25.1 | 5.3 | +10.5% |
| Median | 35.4 | 25.1 | 5.3 | +10.5% |